Clinical trials: Esophagitis
Gastroesophageal Reflux, Heartburn
HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease
Determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.
- Conditions
- Gastroesophageal Reflux, Heartburn, Dyspepsia
- Trial name
- NCT00243724
- Testing
- Esomeprazole
- Where
- 10 sites in Canada
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Eosinophilic Esophagitis
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants…
- Trial name
- NCT04753697
- Testing
- CC-93538
- Where
- 212 sites in United States, Argentina and 13 more
- Volunteers
- 430 people
- Sponsor
- Celgene
Gastroesophageal Reflux Disease, Hiatal Hernia
Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study
The objective of the study is to evaluate the relative merits, safety and effectiveness of the EsophyX transoral device in performing an advanced TIF procedure in patients with "troublesome symptoms" as defined by the Montreal…
- Trial name
- RESPECT (NCT01136980)
- Testing
- TIF Transoral Fundoplication
- Where
- 9 sites in United States
- Volunteers
- 129 people
- Sponsor
- EndoGastric Solutions
Esophagitis, Reflux, Esophagitis, Peptic
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00255151
- Testing
- Dexlansoprazole MR
- Where
- 100 sites in United States
- Volunteers
- 451 people
- Sponsor
- Takeda
Refractory Reflux Esophagitis
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis
- Trial name
- NCT01321567
- Testing
- rabeprazole sodium
- Where
- 447 sites in Japan
- Volunteers
- 2,157 people
- Sponsor
- Eisai Co., Ltd.
Healed Erosive Esophagitis
Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis
This study aims to demonstrate the noninferiority of DWP14012 to Lansoprazole 15 mg in the maintenance effect of treatment and confirm the safety of DWP14012 in patients with healed erosive esophagitis confirmed on EGD after…
- Trial name
- NCT04341428
- Testing
- DWP14012 20 mg, Lansoprazole 15 mg
- Where
- South Korea
- Volunteers
- 406 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Erosive Esophagitis
JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis
To evaluate the efficacy and safety of JP-1366 20 mg compared to esomeprazole 40 mg in patients with erosive esophagitis
- Trial name
- NCT05443984
- Testing
- JP-1366 20mg, Esomeprazole 40mg
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Onconic Therapeutics Inc.
Eosinophilic Esophagitis
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response <15 eosinophils per high-power…
- Trial name
- NCT06851559
- Testing
- Vonoprazan
- Where
- 41 sites in United States
- Volunteers
- 95 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Eosinophilic Esophagitis
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension.
- Trial name
- NCT05634746
- Testing
- APT-1011, Esophagogastroduodenoscopy
- Where
- 60 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Eosinophilic Esophagitis (EoE)
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
- Trial name
- NCT06598462
- Testing
- Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose
- Where
- 73 sites in United States, Australia and 7 more
- Volunteers
- 184 people
- Sponsor
- Uniquity One (UNI)
Eosinophilic Esophagitis
Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)
Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by eosinophilic infiltration and gastrointestinal symptoms.
- Trial name
- FLUTE (NCT03191864)
- Testing
- APT-1011
- Where
- 75 sites in United States, Belgium and 4 more
- Volunteers
- 106 people
- Sponsor
- Adare Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease, Erosive Esophagitis
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
The purpose of this study is to assess the safety and effectiveness of treatment with once daily oral administration of dexlansoprazole delayed-release capsules in adolescents with erosive esophagitis (EE) and for maintenance of…
- Trial name
- NCT01642615
- Testing
- Dexlansoprazole
- Where
- 60 sites in United States, Belgium and 6 more
- Volunteers
- 63 people
- Sponsor
- Takeda
Eosinophilic Esophagitis
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538.
- Trial name
- NCT04991935
- Testing
- CC-93538
- Where
- 167 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Celgene
Eosinophilic Esophagitis (EoE)
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
This is a clinical trial to test an experimental drug for the treatment of Eosinophilic Esophagitis (EoE)
- Trial name
- NCT01642212
- Testing
- Oral Budesonide Suspension (MB-9)
- Where
- 23 sites in United States
- Volunteers
- 93 people
- Sponsor
- Shire
Healed Erosive Esophagitis
Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis
This study is designed to confirm the non-inferiority of Tegoprazan 25mg, compared to Lansoprazole 15mg as maintenance therapy in patients with healed erosive esophagitis confirmed by endoscopy following oral administration once…
- Trial name
- NCT04022096
- Testing
- Tegoprazan 25mg QD, Lansoprazole 15mg QD
- Where
- South Korea
- Volunteers
- 351 people
- Sponsor
- HK inno.N Corporation
Gastroesophageal Reflux
Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease
The purpose of this study is to assess the pharmacokinetics and safety of dexlansoprazole, once daily (QD), in pediatric subjects with symptomatic Gastroesophageal Reflux Disease.
- Trial name
- NCT01045096
- Testing
- Dexlansoprazole
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Takeda
Erosive Esophagitis
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
- Trial name
- EE (NCT05267613)
- Testing
- Nexium 20mg, Nexium 10mg
- Where
- 41 sites in United States, Argentina and 8 more
- Volunteers
- 53 people
- Sponsor
- AstraZeneca
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
This is a Phase 2, open-label, extension study to assess the safety and tolerability of AK002, given monthly for up to 26 doses.
- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
- Trial name
- NCT03664960
- Testing
- AK002
- Where
- 17 sites in United States
- Volunteers
- 58 people
- Sponsor
- Allakos Inc.
Reflux Oesophagitis
Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States
The objectives of the study were: To compare a single dose of YF476 at 3 dose levels, placebo and ranitidine with respect to their effects on basal- and food- stimulated gastric pH in healthy volunteers.
- Trial name
- NCT01538797
- Testing
- YF476, Ranitidine
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Reflux Esophagitis
The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis
To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.
- Trial name
- NCT05813561
- Testing
- DWP14012
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.